Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet...
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 13, 2021 | By Dave Fornell, Editor
(This story was updated May 7, 2021 in the last subheaded section) April 13, 2021 — The U.S. Food and Drug...
Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

News | Stents | April 06, 2021
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual...
Videos | Coronavirus (COVID-19) | April 01, 2021
Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal...
FDA Clears Third COVID-19 Vaccine From Janssen, Johnson and Johnson, J&J
News | Coronavirus (COVID-19) | March 01, 2021
March 1, 2021 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third...
Vaccinating patients against the flu can go a long way to helping cardiology patients stay healthy and out of the hospital during the COVID-19 pandemic, freeing up beds for COVID patients. Left photo, Getty Images, right image of COVID-19 virus from the NIH.

Vaccinating patients against the flu can go a long way to helping cardiology patients stay healthy and out of the hospital during the COVID-19 pandemic, freeing up beds for COVID patients. Left photo, Getty Images, right image of COVID-19 virus from the NIH.

Feature | Coronavirus (COVID-19) | February 23, 2021 | By William Schaffner, M.D., and Allen J. Taylor, M.D.
While influenza (flu) is unpredictable, the 2020-2021 influenza season may present an unprecedented dual threat: co-...
Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium.

Heavily calcified coronary arteries seen on a CT scan of the heart. Research at the New York Institute of Technology will create blood flow modeling to show the impact of calcium in arteries as part of a project to develop treatments to remove calcium. 

News | Cardiovascular Clinical Studies | January 27, 2021
January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the...
FDA clears Verquvo, Vericiguat, Heart failure drug.
News | Heart Failure | January 25, 2021
January 25, 2021 — The U.S. Food and Drug Administration (FDA) approved Merck's Verquvo (vericiguat). It is the first...
The U.S. Government promised to have 20 million people vaccinated by Jan. 1, 2021 with just the Pfizer Vaccine. Even with two vaccines now approved, U.S. vaccinations for COVID stand at less than 4.5 million on Jan. 4, 2020. Getty Images The Pfizer and Moderna COVID vaccines were hailed as a major accomplishment in modern science and as the beginning of the end for COVID. This very well may be true, but it absolutely will not happen as fast as the government has led us to believe. #COVID19 #COVID #SARScov2

The U.S. Government promised to have 20 million healthcare workers and nursing home residents vaccinated by Jan. 1, 2021 with just the Pfizer vaccine. Even with two vaccines now approved, U.S. vaccinations for COVID stand at less than 4.5 million on Jan. 4, 2020. Getty Images

Blog | Coronavirus (COVID-19) | January 04, 2021
There was much fanfare over the U.S. Food and Drug Administration (FDA) emergency use authorizations (EUAs) in December...
Who Can Get the COVID-19 Vaccine? Roberto Lang, M.D., director of noninvasive cardiac imaging, University of Chicago Medical Center and former American Society of Echocardiography (ASE) president, received his first dose of the COVID vaccine in December. In addition to front line hospital workers, nursing home staff and residents also qualified for the first round of vaccinations. Right, Shannon Yaw, a nurse at a hard-hit nursing home in Michigan, received her first dose just before Christmas.

Roberto Lang, M.D., director of noninvasive cardiac imaging, University of Chicago Medical Center and former American Society of Echocardiography (ASE) president, received his first dose of the COVID vaccine in December. In addition to front line hospital workers, nursing home staff and residents also qualified for the first round of vaccinations. Right, Shannon Yaw, OTR/L, director of rehabilitation at a hard-hit nursing home in Michigan, received her first dose just before Christmas.

News | Coronavirus (COVID-19) | January 04, 2021 | Dave Fornell, Editor
The Centers for Disease Control and Prevention (CDC) Dec. 3, released an interim guidance document  to federal, state,...
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al. 

Feature | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants...
The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older. #COVID19 #SARSCoV2 #Vaccine

The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older.

News | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — The U.S. Food and Drug Administration December 18 issued an emergency use authorization (EUA) for a...
The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec, 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance.  #COVID #COVID19 #SARSCoV2 #vaccine #COVIDVaccine

The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec. 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance. 

Feature | Coronavirus (COVID-19) | December 14, 2020 | Dave Fornell, Editor
December 14, 2020 — The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for...
RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News | November 18, 2020
November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial...